As VEGF producing cells often release Stromal Derived Factor 1 alpha that modulates microenvironment and acts on tumor growth [18], [25] we used an antagonist of its CXCR4 receptor, AMD3100 (1.25 mg/kg, twice daily), as an alternative to Bev to reduce tumor growth. The gene discussed is VEGFA; the disease is neoplasm.